Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia signs new clinical account in France

Aiforia Technologies

Translation: Original published in Finnish on 5/19/2025 at 2:14 pm EEST.

Nantes University Hospital will deploy Aiforia's software in clinical diagnostics. The value of the two-year agreement was not communicated in the release. Nantes is the sixth largest university hospital in France, and its catchment area has a population of 800,000. Based on this and the value of Aiforia's previous customer relationships, we estimate that the customer relationship corresponds to less than EUR 100,000 in annual revenue in the initial phase. According to the release, the agreement only includes a part of the company's image recognition models, so the customer relationship has potential for expansion already with the company's current product portfolio. 

This is Aiforia's second clinical segment agreement in France, where the Assistance Publique - Hôpitaux de Paris (AP-HP hospital group) adopted Aiforia in 2024. Although the now-announced agreement is relatively small in size, it still sends a good message about the company's market position and the pace at which the market is forming. The release supports our forecasts of strong revenue growth but does not create pressure for forecast changes.

Login required

This content is only available for logged in users

Create account

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures23.04.

202425e26e
Revenue2.94.77.6
growth-%18.9 %65.7 %60.0 %
EBIT (adj.)-12.2-11.9-12.0
EBIT-% (adj.)-427.8 %-252.9 %-158.1 %
EPS (adj.)-0.41-0.37-0.38
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Interesting observation: If a foundation model is created with a specific scanner, the model learns the scanner’s characteristics, but may not...
1 hour ago
by Vino Pino
8
Here are Antti’s and Frans’s comments on this recent AI platform news. Aiforia announced on Wednesday that it is launching a new generation ...
3 hours ago
by Sijoittaja-alokas
11
New technology promises to accelerate the development of AI models and improve their performance, which supports the expansion of the company...
3 hours ago
by Sami831
4
Aiforia launches next-generation AI technology platform aiforia.com Aiforia launches next-generation AI technology platform Aiforia expands ...
yesterday
by TO
30
Aiforia’s “deep learning neural networks”? facebook.com 1,4 milj. näyttökertaa · 23 t. reaktiota | Totally not winging it:... Totally not winging...
yesterday
by Antti Luiro
19
This also restricts issues in January. Persons discharging managerial responsibilities at the issuer are subject to a 30-day closed period before...
12/12/2025, 3:28 PM
by Zen65
1
Will that ownership list be updated before trading begins with these new shares on the 15th, or will it only be visible at the beginning of ...
12/12/2025, 2:39 PM
by Salvelinus
0
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.